Physician profile
Romi Bloom
NPI 1750735593
$3,360.99
in general payments reported to CMS, 2019-2025
24 companies · $1,236 in 2025
The $1,236 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.33 · 2022: $299 · 2023: $780 · 2024: $949 · 2025: $1,236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,959 · Education: $5.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,959.27 |
| Education | $5.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $588.14 | 2022-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $413.79 | 2022-2025 | |
| Abbvie INC. | $322.96 | 2023-2025 | Rinvoq, Skyrizi |
| Dermavant Sciences, INC. | $306.49 | 2022-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $253.81 | 2022-2025 | |
| Amgen INC. | $209.39 | 2023-2025 | Otezla, Otezla |
| Incyte Corporation | $191.00 | 2022-2025 | Opzelura |
| Lilly USA, LLC | $171.57 | 2022-2024 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $158.20 | 2022-2025 | Winlevi |
| Allergan, INC. | $97.33 | 2019 | |
| Pfizer INC. | $95.18 | 2024-2025 | |
| Galderma Laboratories, L.P. | $92.57 | 2022-2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $71.02 | 2023-2025 | Cabtreo, Jublia |
| Ucb, INC. | $61.89 | 2025 | Bimzelx |
| Janssen Biotech, INC. | $61.21 | 2025 | Tremfya |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $48.42 | 2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.47 | 2023-2024 | Spevigo |
| Biofrontera INC. | $37.56 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Mayne Pharma Commercial LLC | $30.01 | 2025 | |
| Organon LLC | $27.83 | 2025 | Vtama |
| Genentech USA, INC. | $24.73 | 2022 | |
| Botanix Sb INC | $24.01 | 2025 | Sofdra |
| Fresenius Kabi USA, LLC | $17.98 | 2023 | |
| Journey Medical Corporation | $14.43 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Romi Bloom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.